Melanotan-1
FDA ApprovedAlso known as: Afamelanotide, Scenesse, NDP-MSH, [Nle4,D-Phe7]-α-MSH, MT-I, MT-1, CUV1647
An FDA-approved synthetic analog of alpha-MSH that selectively activates MC1R to stimulate eumelanin production. Approved as Scenesse for erythropoietic protoporphyria (EPP), making it the first and only treatment for this rare photosensitivity disorder.
Research Statistics
FDA and EMA approved afamelanotide (Scenesse) for EPP. Two pivotal RCTs (NEJM 2015, N=93 and N=74) across US and European sites. Narrow orphan indication limits total research volume. MC1R-selective agonism mechanism is well-characterized through receptor pharmacology.
Research Dossier
Overview
What is Melanotan-1 and what does the research say?
Mechanism of Action
Melanotan-1 (afamelanotide) is a synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that selectively activates MC1R receptors on melanocytes to stimulate eumelanin production, making it the first FDA-approved treatment for erythropoietic protoporphyria (EPP).
How It Works (Simplified)
Melanotan-1 acts as a targeted MC1R agonist, producing photoprotection through a defined melanocortin signaling cascade:
Afamelanotide binds to MC1R receptors on melanocytes with high selectivity, unlike non-selective Melanotan-II which also activates MC3R, MC4R, and MC5R. This selectivity eliminates the CNS and cardiovascular effects associated with multi-receptor melanocortin agonism.
MC1R activation triggers the intracellular cAMP/PKA/MITF cascade, upregulating tyrosinase and related enzymes (TRP-1, TRP-2). This drives synthesis of eumelanin (dark pigment) rather than pheomelanin, increasing protective pigment density in the epidermis.
Increased epidermal eumelanin absorbs UV radiation before it reaches and excites accumulated protoporphyrin IX (PPIX) in EPP patients. By intercepting the photon energy at the melanin layer, phototoxic PPIX excitation is prevented, dramatically reducing pain episodes.
EPP patients gain significantly more pain-free hours in sunlight — 69.4 vs 40.8 median hours over 6 months in the pivotal US trial. Clinical benefit lasts through 60-day implant cycles, enabling near-normal daily activity for patients previously confined to strict sun avoidance.
Scientific Pathways
MC1R Photoprotection Pathway (Primary EPP Mechanism)
Afamelanotide (MC1R-selective)
→ MC1R activation on melanocytes
→ cAMP increase → PKA activation
→ MITF transcription factor upregulation
→ Tyrosinase/TRP-1/TRP-2 expression
→ Eumelanin synthesis ↑
→ UV absorption in epidermis ↑
→ PPIX phototoxicity ↓ (in EPP)Key Research: Langendonk JG et al. (2015, NEJM) demonstrated in two randomized placebo-controlled trials that afamelanotide significantly increased pain-free sunlight hours in EPP patients, forming the basis for FDA approval in 2019. PMID:26132941
Important Limitations
- Only FDA-approved for erythropoietic protoporphyria (EPP) — all other uses are off-label and unsupported by evidence
- Small trial populations typical of rare disease studies (N=93 US trial, N=74 EU trial); total pivotal trial enrollment under 200 patients
- Subcutaneous implant must be administered by a trained healthcare provider — cannot be self-administered
- Only available through the restricted Scenesse REMS program in the US
- Long-term safety data beyond 5 years is limited
- Does NOT have the same receptor profile as Melanotan-II — safety and efficacy data between the two compounds is not interchangeable
- Off-label cosmetic tanning use is not evidence-based and not recommended
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Afamelanotide implant releases most of its dose within the first 48 hours following subcutaneous implantation. Initial melanocyte activation begins as drug is absorbed systemically. Mild implant site reactions (bruising, swelling) are common during this period.
Visible skin darkening begins as eumelanin synthesis ramps up in epidermal melanocytes. Initial photoprotective effect begins emerging. Clinical trial participants reported gradual increase in tolerable sunlight exposure during this period.
Peak eumelanin levels and maximum photoprotective benefit observed. Pivotal trials showed the greatest increase in pain-free sunlight hours in this window. EPP patients can typically tolerate substantially more outdoor activity compared to pre-treatment baseline.
Sustained protection with repeat implant at 60-day intervals maintains eumelanin levels. Clinical trial protocol required implants every two months to sustain benefit. Real-world data confirms 91% of patients continue treatment long-term due to sustained benefit.
Gradual return to baseline skin pigmentation over approximately 1-3 months as existing eumelanin degrades and new melanin synthesis returns to unstimulated baseline. EPP symptoms typically return as photoprotection wanes. No rebound phenomena or withdrawal effects documented.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Melanotan-1 product quality
Good Signs (6 indicators)
Warning Signs (4 indicators)
Bad Signs (5 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Melanotan-1 with other peptides. Based on published research and mechanistic considerations.
PT-141
CompatibleBoth melanocortin analogs but target different receptors and indications. PT-141 (bremelanotide) is MC4R-preferring for HSDD; Melanotan-1 is MC1R-selective for EPP. No overlapping mechanism of concern.
BPC-157
CompatibleNo known interaction. Different targets — BPC-157 for GI/tissue repair, Melanotan-1 for melanocortin-mediated photoprotection.
Melanotan-II
CautionStructurally related alpha-MSH analogs but fundamentally different. Melanotan-II is non-selective (MC1R+MC3R+MC4R+MC5R) and unapproved with significant safety concerns. Do not combine — overlapping melanocortin pathway activation with unpredictable receptor cross-talk.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Melanotan-1
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3, 225Ac-DOTA-JR11, Alpha-PRRT +1 more
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL, Ala-Glu-Asp-Leu, Bronchial tetrapeptide +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528, EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. Phase 1/2 dose expansion ongoing with 67% ORR reported in EphA2-positive urothelial cancer patients.
Cardiogen
AED, Ala-Glu-Asp, Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp) developed by Russian scientist Vladimir Khavinson for cardiac tissue support. Claimed to target cardiomyocyte gene expression and provide cardioprotective effects. No Western clinical validation exists; evidence limited to Russian preclinical and observational studies.
Chonluten
EDG-GI, Glu-Asp-Gly (GI), GI tract tripeptide +1 more
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01, Evaxion EVX-01, AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1 data in melanoma showed 67% overall response rate when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.